Cargando…

Evaluation of biological pathways involved in chemotherapy response in breast cancer

INTRODUCTION: Our goal was to examine the association between biological pathways and response to chemotherapy in estrogen receptor-positive (ER(+)) and ER-negative (ER(-)) breast tumors separately. METHODS: Gene set enrichment analysis including 852 predefined gene sets was applied to gene expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tordai, Attila, Wang, Jing, Andre, Fabrice, Liedtke, Cornelia, Yan, Kai, Sotiriou, Christos, Hortobagyi, Gabriel N, Symmans, W Fraser, Pusztai, Lajos
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397539/ https://www.ncbi.nlm.nih.gov/pubmed/18445275 http://dx.doi.org/10.1186/bcr2088

Ejemplares similares

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
por: Liedtke, Cornelia, et al.
Publicado: (2008)

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status
por: Hayashi, Naoki, et al.
Publicado: (2017)

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
por: Li, Qiyuan, et al.
Publicado: (2011)

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2007)

A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy
por: Shen, Kui, et al.
Publicado: (2012)

Fingerprinting Lymph Node Metastases
por: Symmans, W. Fraser, et al.
Publicado: (2008)

The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data
por: Wang, Jing, et al.
Publicado: (2009)

A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes
por: Dutta, B, et al.
Publicado: (2012)

Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems
por: Hess, Kenneth R, et al.
Publicado: (2011)

Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient
por: Torikoshi, Yasuhiro, et al.
Publicado: (2013)

Characterization of DNA variants in the human kinome in breast cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile
por: Zhao, Chen, et al.
Publicado: (2011)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer
por: McGovern, Susan L, et al.
Publicado: (2012)

Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses
por: Natowicz, René, et al.
Publicado: (2008)

Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
por: Popovici, Vlad, et al.
Publicado: (2010)

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
por: Marczyk, Michal, et al.
Publicado: (2019)

Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial
por: Shen, Kui, et al.
Publicado: (2012)

Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments
por: Qi, Yuan, et al.
Publicado: (2015)

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
por: Masuda, Hiroko, et al.
Publicado: (2013)

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
por: Bianchini, Giampaolo, et al.
Publicado: (2013)

Maximizing biomarker discovery by minimizing gene signatures
por: Chang, Chang, et al.
Publicado: (2011)

Discovering the chloride pathway in the CFTR channel
por: Farkas, Bianka, et al.
Publicado: (2019)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer
por: Pusztai, L
Publicado: (2011)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

A clinically relevant gene signature in triple negative and basal-like breast cancer
por: Rody, Achim, et al.
Publicado: (2011)

Functional polymorphisms in cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples
por: Fu, Chunxiao, et al.
Publicado: (2021)

The transport pathway in the ABCG2 protein and its regulation revealed by molecular dynamics simulations
por: Nagy, Tamás, et al.
Publicado: (2020)

Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures
por: Karn, Thomas, et al.
Publicado: (2011)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Ink4a/Arf(−/−) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(−) quiescent cells
por: Kai, Kazuharu, et al.
Publicado: (2013)

Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
por: Gonzalez-Angulo, Ana M, et al.
Publicado: (2011)

Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
por: Iwamoto, Takayuki, et al.
Publicado: (2010)

Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics
por: Shiang, Christine, et al.
Publicado: (2010)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
por: Fanucci, Kristina A., et al.
Publicado: (2023)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1vftnhdvjqcb2olvo3666nco3r